Development of a Preclinical Therapeutic Model of Human Brain Metastasis with Chemoradiotherapy by Martínez Aranda, Antonio et al.
Int. J. Mol. Sci. 2013, 14, 8306-8327; doi:10.3390/ijms14048306 
 
International Journal of 
Molecular Sciences 
ISSN 1422-0067 
www.mdpi.com/journal/ijms 
Article 
Development of a Preclinical Therapeutic Model of Human 
Brain Metastasis with Chemoradiotherapy  
Antonio Martínez-Aranda 1,2, Vanessa Hernández 1, Cristina Picón 3, Ignasi Modolell 3 and 
Angels Sierra 1,* 
1 Biological Clues of the Invasive and Metastatic Phenotype Group, Bellvitge Biomedical Research 
Institute (IDIBELL), L’ Hospitalet de Llobregat, Barcelona 08907, Spain;  
E-Mails: amartinez@idibell.cat (A.M.-A.); vhernanadez@idibell.cat (V.H.)  
2 Autonoma University of Barcelona (UAB), Faculty of Biosciences, Campus Bellaterra, Building C, 
Cerdanyola del Vallés, Barcelona 08193, Spain 
3 Medical Physics Service, Oncology Catalan Institut, Duran I Reynals Hospital,  
L’Hospitalet de Llobregat, Barcelona 08907, Spain; E-Mails: cpicon@iconcologia.net (C.P.); 
imodolell@iconcologia.net (I.M.) 
* Author to whom correspondence should be addressed; E-Mail: asierra@idibell.cat;  
Tel.: +34-93-260-7429, Fax: +34-93-260-7426. 
Received: 30 November 2012; in revised form: 16 March 2013 / Accepted: 26 March 2013 /  
Published: 16 April 2013 
 
Abstract: Currently, survival of breast cancer patients with brain metastasis ranges from 2 
to 16 months. In experimental brain metastasis studies, only 10% of lesions with the 
highest permeability exhibited cytotoxic responses to paclitaxel or doxorubicin. Therefore, 
radiation is the most frequently used treatment, and sensitizing agents, which synergize 
with radiation, can improve the efficacy of the therapy. In this study we used 435-Br1 cells 
containing the fluorescent protein (eGFP) gene and the photinus luciferase (PLuc) gene to 
develop a new brain metastatic cell model in mice through five in vivo/in vitro rounds.  
BR-eGFP-CMV/Luc-V5 brain metastatic cells induce parenchymal brain metastasis within 
60.8 ± 13.8 days of intracarotid injection in all mice. We used this model to standardize a 
preclinical chemoradiotherapy protocol comprising three 5.5 Gy fractions delivered on 
consecutive days (overall dose of 16.5 Gy) which improved survival with regard to 
controls (60.29 ± 8.65 vs. 47.20 ± 11.14). Moreover, the combination of radiotherapy with 
temozolomide, 60 mg/Kg/day orally for five consecutive days doubled survival time of the 
mice 121.56 ± 52.53 days (Kaplan-Meier Curve, p < 0.001). This new preclinical 
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chemoradiotherapy protocol proved useful for the study of radiation response/resistance in 
brain metastasis, either alone or in combination with new sensitizing agents.  
Keywords: brain metastasis; breast cancer; experimental models; radiation;  
temozolomide; therapy 
 
1. Introduction 
Although breast cancer metastasis to either the brain parenchyma or the leptomeninges is generally 
a late feature of the disease, metastasis to the central nervous system (CNS) is associated with a dismal 
prognosis [1] and causes significant morbidity and mortality in breast cancer patients [2]. Indeed,  
30%–40% of patients with disseminated breast carcinoma develop metastasis in the CNS, with 
survival ranging from 2 to 16 months [3].  
The high rate of CNS metastasis may be related to the greater survival in patients receiving 
chemotherapy and to the difficulty that current systemic treatments have in overcoming the blood brain 
barrier (BBB) [3–5]. The amplification of the ErbB2 receptor tyrosine kinase or triple negative tumors 
(negative estrogen and progesterone receptors and normal ErbB2 expression) increases the incidence 
of brain metastases, which may exceed 30% of patients [6,7]. 
The mechanistic process in the pathogenesis of brain metastasis is complex because cancer cells 
have to cross the blood brain barrier (BBB) located in the brain vascular endothelium [8]. The brain 
places different demands on the invading tumor cells, which are obliged to establish glial interactions 
in order to colonize it [9]. Many issues such as the mechanism of arrest and the role of cell 
extravasation, angiogenesis, and dormancy remain controversial [10]. The essential step takes place at 
the vascular branch point, where the persistent close contact between metastatic cells and microvessels 
induces perivascular growth via vessel cooption [11]. The extracellular matrix, pericytes and astrocyte 
foot processes mediate the impermeability of the BBB, which is increased by the high electrical 
resistance in brain capillaries hindering the entrance of polar and ionic substrates [12].  
The BBB remains a significant impediment to the delivery and efficacy of standard chemotherapy 
for brain metastasis of breast cancer [13]. Experimental brain metastasis studies showed that most 
metastases exhibit increased BBB permeability, which is poorly correlated with lesion size, and that 
only 10% of lesions with the highest permeability exhibited cytotoxic responses to paclitaxel or 
doxorubicin [14]. This evidence reinforces the need for brain-permeable molecular therapeutics and 
radiation-sensitizing agents able to synergize with radiation therapy, thus improving the treatment of 
established brain metastases and minimizing the cognitive losses suffered by a proportion of patients 
after radiotherapy [15,16].  
In this scenario, models mimicking brain metastasis are needed to examine the pathogenesis in 
more depth and to develop experimental therapeutic approaches able to improve our understanding of 
antimetastatic activity and toxicity of numerous experimental agents [17,18]. The major problem is 
that tumor foci occasionally grow in the brain and successive rounds of systemic injections are needed 
to increase the propensity of breast cancer cells to metastasize in brain [19]. Schackert and Fidler 
(1988) described an animal model of brain metastasis, based on intracarotid (CA) injection of human 
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cell lines in nude mice [20], which they used to characterize melanoma brain metastasis and various 
types of carcinoma [13]. In earlier work we modified this method, which progressed within a 20 to  
62-day time window post–injection in 69% of cases, as detected by in vivo MR and further confirmed 
by the histological analysis of samples [21].  
Mouse models of breast cancer and advanced metastatic disease are needed in order to be able to 
carry out preclinical therapeutic studies. Since radiation therapy is the most commonly used procedure 
for the treatment of brain metastasis, we used triple negative 435-Br1 cells containing the fluorescent 
protein (eGFP) gene and the photinus luciferase (PLuc) gene, in order to develop a new brain 
metastatic cell variant which induced parenchymal brain metastasis within a 60-day time window  
post-injection in all cases. BR-eGFP-CMV/Luc cells were injected in the left ventricle and their further 
isolation from mouse brain was repeated five times, obtaining BR-eGFP-CMV/LucV5 cells through 
these cycles (BRV5).  
Temozolomide (TMZ) has been broadly used in glioblastoma experimental therapeutic models and 
in clinical settings, objectivizing regression or delay of tumor progression [22–25]. Studies in patients 
show that association of whole brain radiation plus TMZ for brain metastasis treatment is well 
tolerated [26]. As an oral anticancer agent, has a favorable toxicity and pharmacokinetic profile, 
allowing its clinical investigation for brain metastasis from solid tumors in combination with other 
treatments, such as radiotherapy [27]. Using BRV5 cells and BRV5CA1 cells (obtained from brain 
metastasis after intracarotid, IC, injection of BRV5 cells), we standardized a preclinical protocol 
combining radiotherapy and TMZ, as radiosensitizer, that can be used to assess new drugs and/or new 
radiation protocols to combat breast cancer brain metastasis. This versatile model mimics triple 
negative breast cancer clinical brain metastasis growth, which can be analyzed in vivo when mice are 
submitted to different therapeutic protocols.  
2. Results  
2.1. BR-eGFP-CMV/Luc-V5 Brain Metastatic Cells 
A cell population that uniformly expressed the highest levels of eGFP (BR-eGFP-CMV/Luc) was 
selected by FACS and was used as a starting point for the selection of more specific brain metastatic 
cells (Figure 1A). We started by injecting BR-eGFP-CMV/Luc cells into the left ventricle and 
continued until five in vivo/in vitro rounds, before intracarotid injection (Figure 1B).  
435-Br1 cells have been the mainstay of experimental brain metastasis via infusion into either the 
carotid artery or the left cardiac ventricle [20,28]. In previous work we reported that 435Br1 metastatic 
cells have a heterogeneous distribution, secondary to the entry points of the cells in the brain 
parenchyma, which was confirmed by the histological analysis of ex vivo samples [21]. Five minutes 
after CA injection of BRV5 cells their presence in vessels was confirmed by fluorescence microscopy, 
which identified them in the lumen of the intraparenchymal brain arteries (see Figure 2A). These 
results are in agreement with reports of a strong bioluminescence signal immediately after carotid 
injection of MDA-BM-435 cells, which was detected in the hemisphere of the brain and persisted at 
the same level of intensity through days 5 to 7 before the exponential increase [29]. 
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Figure 1. BR-eGFP-CMV/Luc brain metastatic cells. (A) Cells viewed under fluorescence 
microscopy in culture (20×); (B) Flow work chart of Inoculation of BR-eGFP-CMV/Luc 
cells in left ventricle. The diagram shows the steps followed to obtain cells that have been 
inoculated five times in the left ventricle of female athymic mice. The cells obtained from 
the brain when mice were injected for the first time in the left ventricle are named V1 cells, 
and those obtained after the fifth injection are named V5 cells (BRV5 cells). Further 
intracarotid injection experiments were performed using these V5 cells and then isolated 
from brain tissue (BRV5CA1 cells); (C) Statistical analysis comparing survival of mice 
injected with BRV3 and BRV5 cells (Mann-Whitney Test, 2-tailed, p = 0.016). 
 
 
The fourth round we injected BR-eGFP-CMV/Luc-V3 (BRV3) cells into the left ventricle inducing 
mainly mediastinal lymph node metastases that killed five out of five mice 33.8 ± 10.9 days after cells 
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inoculation. Fluorescent cells were found in the brain of two of five mice, in the lungs in five, in the 
liver in four, in the ovaries in two, in suprarenal glands in one and in mediastinal lymph nodes in five 
(Table 1). BR-eGFP-CMV/Luc-V5 (BRV5) cells that were injected intracarotid induced symptoms of 
brain disabilities in five mice, consisting in lateralization of the movements and asymmetry in addition 
to loss of weight. We found fluorescent cells in the brain of all five mice studied, in the lungs in five, 
in the liver in one, in the ovaries in two, in suprarenal glands in three and in mediastinal lymph nodes 
in three (Table 1). All mice showed symptoms of brain disabilities with a median of survival of  
60.8 ± 13.8 days after cells inoculation (Figure 1C). Since the mice died without symptoms of 
breathing difficulties and without macroscopic metastasis in lungs or lymph nodes, the brain metastasis 
observed in histological slides indicated that brain metastasis progression was the cause of death. 
Differences in the survival evolution of mice inoculated with BRV3 cells with regard to those 
inoculated with BRV5 cells were statistically significant (Mann-Whitney Test, 2-tailed p = 0.016).  
Table 1. Distribution of organs with progressive metastatic colonization in BRV3 vs. 
BRV5 cells inoculated mice. 
Via left ventricle Via internal carotid artery	
V3 (n = 5 ) V5 (n = 5 ) 
positive GFP-Luc cells positive GFP-Luc cells 
Brain 2/5 (40%) 5/5 (100%) 
Lungs 5/5 (100%) 5/5 (100%) 
Liver 4/5 (80%) 1/5 (20%) 
Suprarenal glands 1/5 (20%) 3/5 (60%) 
Ovaries 2/5 (40%) 2/5 (40%) 
Mediastinic Lymph Nodes 5/5 (100%) 3/5 (60%) 
Abdominal Lymph Nodes 1/5 (20%) 1/5 (20%) 
The perioperative mortality following LV injection was 11% vs. 8% in mice in which brain 
metastases were induced via IC.  
We used MRI for in vivo visualization of the parenchymal location of brain metastases (Figure 2B). 
As expected, the longitudinal studies of metastatic progression in coronal (Figure 2B left) and axial 
sections (Figure 2B right) identified metastasis mainly in the brain parenchyma. After inoculation in 
the right carotid artery, MRI scans (T2w and high resolution sequences) on coronal and axial planes 
were acquired weekly. Images obtained at day 7, 14 and 21 post-inoculation showed no abnormal 
signal in the brain, and no clinical symptoms were observed. At day 29 when the animals showed some 
external signs of illness, such as a slight increase in the size of the right eye and hypoactivity, MRI 
showed small lesions in the right hemisphere of the brain. Post-mortem histological analyses in 
transversal and coronal slices were carried out in most cases to confirm the extension of the disease, 
staining the slides with hematoxylin and eosin (Figure 2C).  
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Figure 2. Histological view of cells inoculated in mice by intracarotid injection. (A) 20 µm 
slice from CD1 female mouse brain 5 min after intracarotid injection of cells seen under 
fluorescence microscope (40×). Note the fluorescence from the inoculated cells in the 
lumen of the brain vessels (see black arrow); (B) Magnetic resonance imaging scans (T2w 
and high resolution sequences) on coronal (left) and axial (right) planes respectively from 
a mouse skull 29 days post-injection of BR-eGFP-CMV/Luc (V5CA1) cells. In both scans 
several small lesions can be seen in the right hemisphere of the brain (see red arrows);  
(C) H&E staining of a 5 µm histological slice (4×) from right brain hemisphere 30 days  
post-injection in the right carotid artery of BR-eGFP-CMV/Luc (V5CA1) cells. Note  
the two metastases of different sizes (see black arrows). On the right is the largest  
metastasis at (20×). 
 
2.2. The Therapeutic Irradiation Model 
Radiation therapy is the most commonly used clinical procedure for the treatment of brain 
metastases. We aimed to standardize an experimental radiation model for application in preclinical 
radiation therapies. We used a scalpel to mold several beds on the bolus (one for each mouse’s head) in 
order to keep all the heads in the supine position during CT scanning and treatment. When mice were 
anesthetized in the flux chamber, they were laid on the bolus surface in the supine position, with their 
heads fitted in the molded beds after securing their bodies in position with sticking-plaster  
(Figure 3A–E). A piece of molded bolus covered their heads; care was taken not to disturb  
the breathing.  
A 
C 
B 
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Figure 3. Standardization of the experimental radiation model box. (A) The molded bolus 
was placed in the plastic box. Black lines are drawn on the four sides of the box indicating 
the position of the bolus. In the treatment room, laser lines used for alignment (red 
brackets) pass through the black lines to ensure good and reproducible alignment 
throughout the treatment; (B) Anesthetized mice laid on the bolus surface in supine 
position, with their heads fitted in the molded beds and their bodies kept in position by 
means of sticking-plaster; (C) Placement of bolus with fixed animals according to the 
position of the black marks. Yellow rectangle indicates the projection of the treatment field 
size and the red crossline the direction of the alignment laser lights on the treatment table; 
(D) Other molded bolus covering the heads of the mice for CT scanning and treatment.  
(E) The depths at which brains are placed with regard to the box surface (between 2.3 and 
3.0 cm depth) and the isodose curve distribution at these depths. SSD: Source Surface 
Distance = 100 cm. The figure also shows how the brains are irradiated. 
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Figure 3. Cont. 
 
After the head CT scans were performed, they were processed by the planning software by 
calculating the dose distribution (isodose curves) of ionizing radiation in brain tissue from the CT 
slices. This procedure provided precise information about the relevant physical parameters, the dose 
distribution, the energy value of the chosen X-rays and prescription data (Figure 3E). The radiation 
treatment schedule was then planned to ensure that the dose delivered to the brain was always the same 
throughout all the treatment sessions. 
For radiobiological assessments in radiotherapy, the linear–quadratic model (L–Q model) is widely 
used [30]. This mathematical model provided a way to calculate the change of fractionation between 
two treatment schedules needed to maintain the same isoeffect in both the tumor and healthy tissue, 
taking into account the number of fractions and the dose per fraction. The balance between antitumoral 
efficacy and tolerance in healthy tissues permitted the assessment of the isoeffect in different treatment 
schedules. We selected the schedule based on 5.5 Gy/fx × 1 fx/day × 3 days (overall dose: 16.5 Gy) 
firstly because the dose delivered to the healthy brain was smaller than those delivered with the  
3 Gy/fx × 1 fx/day × 10 days schedule (overall dose: 30 Gy), reducing the risk of early death by brain 
toxicity, and secondly because the treatment period was shorter and animals received intraperitoneal 
anaesthesia for only three consecutive days.  
The experimental protocol was accordance with the role of whole brain radiotherapy (WBRT) in 
preventing brain metastasis. In humans, the treatment of choice for brain metastasis in most cases is 
WBRT, regardless of the histological type. One of the standard schedules is 3 Gy/fraction, delivering one 
fraction/day for ten days, with an overall delivered dose (OD) of 30 Gy (3 Gy/fx × 1 fx/day × 10 day). 
We tested this treatment schedule in several preliminary studies by delivering it to the whole brain of 
mice with variable degrees of immunodeficiency. First, we checked the survival of CD1 and Nude 
Balb/c female mice exposed to this schedule, and found that CD1 mice survived more than five months 
100 -104 %
6 MV X -rays
SSD=100 cm
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E
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without clinical signs of brain damage or loss of weight; only corneal opacity was observed. The Nude 
Balb/c female mice treated with the same protocol died two months after the radiation therapy  
(data not shown). 
The treatment schedule was performed in brains of female Athymic Nude-Foxn1nu mice at  
a depth of between 2.3 and 3.0 cm from the bolus surface. Taking into account the balance between 
efficacy/tolerance, one fraction (5.5 Gy) was delivered for three days (overall dose: 16.5 Gy); the dose 
rate was 240 Monitor Units (MU/min). The results showed improved survival of mice treated with 
radiotherapy with regard to controls (60.29 ± 8.65 vs. 47.20 ± 11.14, Kaplan-Meier, Log Rank:  
Chi-Square 2.456; df = 1; p = 0.117).  
The apparent differences between BRV5 and BRV5CA1 controls were not significant  
(Kaplan-Meier. Log-Rank test; p = 0.228) and may have been due to the biological variability through 
in vivo experiments and the more aggressive phenotype obtained with BRV5CA1 cells. 
These schedule based on a 5.5 Gy/fraction delivered in one fraction/day for three days, with an 
overall dose of 16.5 Gy was tested in several kinds of immunodeficient mice. Female athymic mice 
survived at least six months after radiotherapy without loss of weight, while NOD/SCID female mice 
died within eight days of radiotherapy which induced extreme weight loss (data not shown). This 
evidence suggests that radiosensitivity is dependent on the mouse model used, particularly on the 
immunological status of mice.  
2.3. Combined Irradiation and Chemotherapy to Treat Experimental Brain Metastasis 
Most clinical trials for brain metastasis enroll patients who have progressed after WBRT treatment, 
or test the therapy in combination with WBRT. In order to optimize the therapeutic model, we performed 
experiments combining radiation with radiosensitization by the DNA methylation agent temozolomide, 
which is currently undergoing clinical evaluation for cancer therapy [6]. As temozolomide has been 
shown to increase survival rates of patients with malignant gliomas when combined with radiation [31], 
we investigated its possible enhancing effect on radiosensitivity (Figure 4).  
The TMZ dose was selected on the basis of previous studies on glioma models using TMZ at a dose 
of 100 mg/Kg/day delivered intraperitoneally [32]. Since other tumour xenograft model studies 
evaluated TMZ at 200 mg/Kg/week (100 mg/Kg/day for two days a week) intragastrically for several 
weeks, the maximum tolerated dose was not studied. Moreover, in humans a reduction in the daily 
dose of TMZ is needed when the drug is delivered concurrently with radiotherapy due to TMZ’s 
concomitant toxicity [33]. Thus, in our model, in which TMZ was administered concomitantly with 
radiotherapy, we decided to use a reduced dose of TMZ (60 mg/Kg/day) to decrease the risk of death 
due to toxicity.  
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Figure 4. Schedule of treatment for each group of study: dimethyl sulfoxide (DMSO) 
vehicle alone for control group (n = 5); radiotherapy alone for radiotherapy group (n = 7); 
and concomitant chemoradiotherapy for radiotherapy plus temozolomide (TMZ) group  
(n = 9). The first day of treatment was 26 days after IC injection of cells when 
bioluminescence analysis showed brain metastasis growth. The treatment was applied on 
five consecutive days. 
 
Mice began the treatment on day 26 after brain metastases were induced, when the follow-up 
bioluminescence indicated metastasis development. The control group received DMSO solution orally 
on five consecutive days. Radiotherapy (cranial irradiation 5.5 Gy) was administered on three 
consecutive days starting on the 27th day after the IC injection of cells. In addition, DMSO + TMZ 
solution was delivered orally from day 26 post-IC inoculation of cells on five consecutive days. On 
days 2–4 TMZ was administered one hour before cranial irradiation (cranial irradiation 5.5 Gy), as 
described in the protocol (Figure 5).  
Brain metastasis evolution in mice treated with 5.5 Gy/fraction, delivered one fraction/day for three 
days (days 2–4, overall dose: 16.5 Gy), were compared with mice treated with radiotherapy plus 
chemotherapy (RT + TMZ), which received 20 µL DMSO + TMZ and 180 µL saline orally (final 
volume delivered: 200 µL), every day for five days (days 1–5) and 5.5 Gy/fraction, delivered one 
fraction/day for three days (days 2–4, overall dose: 16.5 Gy). Brain metastases were followed by 
luminescence and the evolution of the treated groups was compared with that of a control group which 
received the vehicle orally (Figure 5A, Table 2). Indeed, 42 days after starting the treatment 
differences were recorded in brain metastasis burden between RT alone and RT + TMZ (Figure 5B). 
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By the end of the experiment survival was significantly higher in the RT + TMZ group  
(121.56 ± 52.53 days) than in the RT alone group (60.28 ± 8.65 days), RT vs. RT + TMZ, Log Rank: 
Chi-Square 13.669; df = 1; p < 0.001. These results demonstrate the benefit of chemoradiotherapy for 
treating breast cancer brain metastasis (Figure 5C). 
Table 2. Comparison of controls, treated with radiotherapy alone or in combination  
with chemotherapy. 
Day 26 31 34 39 42 
control vs. RT 0.2039 0.2348 0.0526 - - 
control vs. RT+TMZ 0.2639 0.0552 0.0115 (*) - - 
RT vs. RT+TMZ 0.7024 0.1813 0.3024 0.3337 0.0589 
* p-value is obtained according the median metastatic burden in the brain in each group: controls N = 5,  
RT N = 7 and RT + TMZ N = 9 (Student “t” test; 2-tailed). 
Figure 5. Combined irradiation and chemotherapy to treat brain metastasis. (A) Control 
mice, mice treated with radiotherapy and mice treated with chemoradiotherapy were 
compared from day 26 to 42 after injecting cells in CA. The evolution of metastasis growth 
is shown according the signal of luminescent cells; (B) The median of metastatic burden of 
mice treated with radiotherapy and treated with chemoradiotherapy was compared from the 
starting point of the induction of metastasis; (C) The survival evolution is indicated in the 
Kaplan-Meier Curve (Log Rank -Mantel-Cox-: Chi-Square 22.022; df = 2; p < 0.001). 
Control vs. RT: Log Rank (Mantel-Cox): Chi-Square 2.456; df = 1; p = 0.117. RT vs.  
RT + TMZ: Log Rank (Mantel-Cox): Chi-Square 13.669; df = 1; p < 0.001. Control vs.  
RT + TMZ: Log Rank (Mantel-Cox): Chi-Square 16.649; df = 1; p < 0.001. 
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Figure 5. Cont. 
 
 
3. Discussion 
Metastasis research is highly dependent on reliable animal models that allow different aspects of 
metastasis initiation and progression to be studied in vivo. As these pathologies cannot be studied 
longitudinally in humans for evident ethical reasons, in vivo follow-up studies require animal models 
that can accurately reflect the process observed in humans [16,17]. To develop a more efficient model 
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of brain metastasis from advanced breast cancer we used 435-Br1 brain metastatic cells, established 
from brain metastasis in nude mice, which has been functionally characterized elsewhere [34]. Thus, 
by injecting cells into the LV and recover them from the brain metastasis we increased specificity  
due to the selection of cells that are able to cross the blood brain barrier and to adapt to the  
brain microenvironment. 
The BRV5CA1 cells injected via the IC induced histologically confirmed metastases in 100% of 
animals, but no large masses developed either in the jaw or the neck. Moreover, in our study, 
bioluminescence images showed cranial signals in 19/23 animals (83%) on day 26 post-injection (just 
before the start of the treatment protocol). These results significantly improve the brain metastasis 
evolution of 435Br1 cells, since in our previous magnetic resonance imaging (MRI)/spectroscopy 
(MRS) characterization [21] brain lesions were localized in different brain regions in 69% of animals, 
which were further histologically confirmed in 61% of cases. Since other metastases appeared in the 
neck and the right jaw, progressing rapidly and causing feeding problems in mice, the global procedure 
was inefficient. The selection procedure through five in vivo/in vitro passages of 435Br1 cells induced 
BRV5CA1 cells with a better efficiency and specificity for developing clinical brain metastasis. 
It is known that arrest of individual tumor cells in brain capillaries induces diverse astrocytic and 
microglial responses, resulting in heterogeneous local changes of the initial tumor microenvironment, 
which in turn could restrict the progression of metastatic cells into macrometastases [29]. The survival 
of arrested cancer cells within brain capillaries may be a rate-limiting step in metastatic progression, 
since cancer cell penetration of the vessel wall in the brain is much slower than in progression and 
impacts the success of tumor cells to survive and grow within the brain [35–37].  
The current incidence of brain metastasis seems to be the paradoxical result of the effectiveness of 
drugs that do not cross the blood brain barrier (BBB). In this study of the effectiveness of an 
experimental approach combining radiation and chemotherapy we selected temozolomide, an 
alkylating agent which to our knowledge has not been fully introduced in treatment protocols for breast 
cancer brain metastasis although in patients with brain metastatic breast cancer no responses have been 
reported when was used as a single agent [38]. Different response degrees have been reported in 
patients with melanoma or non-small cell lung cancer brain metastasis treated with TMZ concomintant 
with whole brain radiation [39–41]. Further studies are needed to demonstrate the benefits of TMZ 
concomitant with radiation therapy on breast cancer brain metastasis. 
Trials with TMZ as a radiosensitizer to treat breast cancer brain metastasis are underway [42]. The 
treatment schedule is based on whole brain radiotherapy at 3 Gy/day administered over a two-week 
period and an induction with TMZ 75 mg/m2/day during this period, following TMZ 750 mg/m2 
(fractionated). Moreover, in a phase II study, Siena, et al. [43] reported a dose-dense temozolomide 
regimen for treatment of brain metastasis in which patients had median progression-free survivals of 
56, 58, and 66 days for melanoma, breast cancer, and non-small cell lung. New clinical trials are 
underway to supplement the action of temozolamide with pegylated liposomal doxorubicin, showing 
an overall response rate of 36.8% and a significant improvement in quality of life [44]. Furthermore, 
drug pharmacokinetics and biodistribution may be increased using nanocarriers to enhanced drug 
delivery into the brain improving drug accumulation [45,46]. 
The role of systemic chemotherapy other organs [47]. Moreover, it is well established that the host 
microenvironment affects metastasis in patients with brain metastases remains unclear [48]. Treatment 
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of brain metastasis in breast cancers includes surgery and radiation therapy, since the efficacy of 
chemotherapy for brain metastases remains disappointing [49]. In clinical studies, particularly in  
non-small-cell lung cancer radiotherapy reduced the incidence of brain metastasis, but did not achieve 
any substantial survival benefit [16,50]. Although reported response rates range from 56% to 82% in 
patients with primary cancer of the lung and breast the associated adverse events are severe [50,51]. 
Clearly, a chemotherapeutic agent that is both efficacious and well tolerated would hold great potential 
for the treatment of patients with brain metastases from solid tumors [52]. 
Most clinical trials for brain metastases enroll patients with diagnosed brain metastasis and test an 
experimental therapy in combination with WBRT. Little effect on patient survival has been achieved. 
This experimental chemoradiotherapy model of brain metastasis provides a reproducible method for 
checking new drugs and can help to establish new therapeutic protocols.  
4. Experimental Section  
4.1. Cells and Primary Cultures 
435-Br1 human mammary carcinoma cells (originally established from a brain metastasis in a  
nude mouse orthotopically inoculated with the triple negative parental cell line, MDA-MB-435, kindly 
supplied by Dr. Fabra, IDIBELL, in 1992) were maintained under standard conditions in 1:1 (v/v) 
mixture of DMEM and Ham F12 medium, DMEM/F12 (Life Technologies, Inc. Gibco BRL, 
Gaithersburg, MD, USA). This mixture was supplemented with 10% fetal bovine serum (FBS), 1 mM 
pyruvate, and 2 mM L-glutamine in a 5% CO2 environment at 37 °C in a humidified incubator [9]. 
Although a controversial point, it has recently been demonstrated that MDA-MB-435 cells represent a 
useful breast cancer model and that they express both epithelial and melanocytic markers [53]. 
435-Br1 cells in exponential growth phase were first treated with Trypsine-EDTA (Life 
Technologies, Gaithersburg, MD, USA) for 1 min at room temperature for inoculation. They were then 
washed twice in HBSS and counted using a Neubäuer chamber. Viability (measured by Trypan-Blue 
exclusion) was always between 90% and 97%. 435-Br1 cells were then resuspended in HBSS (Hanks’ 
Buffer Saline Solution) to obtain a final concentration of 1 × 106 cells/100 μL for inoculation either 
into the left ventricle (LV) or into the internal carotid artery (CA) of mice, using a slight modification 
of a previously described method [21]. 
Primary cultures were performed in DMEM F-12 with 50% FBS (Fetal Bovine Serum) (v/v), 2%  
L-glutamine plus pyruvate (v/v), Penicillin 1 mg/mL, Streptomycin 1 mg/mL, Neomycin 2 mg/mL 
(from antibiotic PSN 100× solution, Gibco, Gaithersburg, MD, USA), Gentamicin 0.2 mg/mL and 
Amphotericin-B (Fungizone) 2.5 µg/mL. After culture, if cells showed optimum growth, we reduced 
FBS to 20% and gradually removed the antibiotic solution. Finally, we worked with the standard 
medium DMEM F-12 10% FBS with L-glutamine and pyruvate without bacterial or fungal 
contamination. Mycoplasma-free status was checked before preparing the cells for the next 
inoculation, in order to obtain metastatic cells with a greater affinity to seed in the mouse brain after 
five cycles of inoculation in LV.  
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4.2. Retroviral Transduction 
To label 435-Br1 brain metastatic cells we used the retroviral vector preGFP-CMV-PLuc, which 
contained the enhanced green fluorescent protein (eGFP) gene, under control of the 5' LTR, and the 
photinus luciferase (PLuc) gene, under control of the cytomegalovirus (CMV) promoter. Retroviral 
transduction was used to label 435-Br1 brain metastatic cells. Vector preparation and packaging of 
viral particles was performed as described previously [54]. A cell population that uniformly expressed 
the highest levels of eGFP (BR-eGFP-CMV/Luc) was selected by FACS (MoFlo, Cytomation,  
Dako, Denmark).  
4.3. Brain Metastasis Model and in Vivo Experiments 
Athymic Nude-Foxn1nu female mice 22–28 g weight were purchased from Charles-River 
Laboratories (Wilmington, MA, USA) and were housed at the IDIBELL facility in SFP conditions, 
with 20–24 °C cage temperature, 60% relative humidity, and 12–12 h light-dark periods. Animals were 
allowed free access to UV irradiated water and an adequate sterile diet. All animal-related procedures 
were performed in accordance with the National Institute of Health Guidelines for the Care and Use of 
Laboratory Animals, with the approval of the animal care committee.  
Briefly, mice were anesthetized with ketamine and xilacine solution (ketamine: 100 mg/Kg; 
xilacine: 10 mg/Kg) injected intraperitoneally before to inoculate cells into the LV. The procedure was 
performed under sterile conditions in a flux chamber and after cleaning the skin with antiseptic iodine 
solution. The ribs were visualized by opening the skin lengthwise at the left parasternal line, and  
1 × 106 BR-eGFP-CMV/Luc cells/100 µL HBSS were injected between the third and fourth ribs 
perpendicularly to the chest surface. Finally, we closed the skin with staples. Animals were sacrificed 
by means of intraperitoneal injection of sodium pentobarbital (Dolethal®), according to their weight, 
when clinical signs of illness or weight loss were detected. The brain and other organs such as lungs, 
liver, suprarenal glands, ovaries, mediastinal and abdominal lymph nodes were then removed and 
examined under a fluorescent microscope for the presence of BR-eGFP-CMV/Luc cells. Cells isolated 
from brain tissue underwent primary culture processes. LV injection of cells and their further isolation 
from mouse brain was repeated five times, obtaining BR-eGFP-CMV/Luc-V1 to V5 cells through 
these cycles.  
To induce brain metastases by CA inoculation, supine mice were anesthetized with inhalatory 
anesthesia under sterile conditions in a flux chamber using a mixture of O2 and isofluorane at 5% (with 
a flux of 4 L/min) for induction, and isofluorane at 1.5%–2.0% (with a flux of 0.3 L/min) for 
maintenance. The whole neck was then disinfected with antiseptic iodine solution and glucosaline s.c. 
(20 mL/Kg per day for two days) was injected to maintain good hydration and meloxicam 5% s.c.  
(100 µL/20 gr per day for two days), to achieve an optimum analgesic/anti-inflammatory effect. The 
neck skin was then opened with an incision like an “inverted seven” (first lengthwise and then 
sideways to the right), thus obtaining a wide surgical field. All soft tissues were dissected, releasing the 
structures carefully to identify clearly the right carotid artery with its main branches. Then, we 
clamped (Vascular Clamps F.S.T. ref.00396-01–S&T, Switzerland) the root of the external carotid 
artery, under the origin of its occipital branch, and then the stapedial branch, located cranially and deep 
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in the neck. In this way we ensured that most of the inoculated cells (1 × 106 of BR-eGFP-CMV/Luc 
(V5) cells/100 µL HBSS) with a Hamilton® syringe (100 µL Bonaduz, Switzerland) and a Hamilton® 
needle (33 Gauge, PK6) would slowly access the brain through the internal carotid artery. Using a pair 
of tweezers, we grasped the common carotid artery caudally near the base of the neck and maintained 
it immobile during the injection. The injection point of the cellular suspension was chosen just above 
this site. Once the needle was inside the common carotid artery lumen, we inserted it in the internal 
carotid branch lumen and then delivered the cellular suspension, pushing slowly at the point of 
injection until the bleeding stopped. Finally, we finished applying the iodine solution in the surgical 
bed and clamped the skin by means of staples. We then stopped the isofluorane mixture and delivered 
a high concentration of O2 for a few seconds before placing the mice under a dry hot source. 
Animals were sacrificed by means of intraperitoneal injection of sodium pentobarbital (Dolethal®) 
according to their weight when clinical signs of illness or loss of weight were detected. 
BR-eGFP-CMV/Luc-V5CA cells were inoculated into CA of mice for the chemoradiotherapy 
experiment. 
4.4. In Vivo Set-up 
Athimic mice inoculated with BR-eGFP-CMV/Luc (V5CA) cells in right carotid artery were 
explored with magnetic resonance imaging sequences in a high-field (7T) horizontal spectrometer at 
29 days post-injection. These studies were carried out at the joint NMR facility of the Universitat 
Autònoma de Barcelona and CIBER-BBN (Cerdanyola del Vallès, Spain), using a 7 T horizontal 
magnet (BioSpec 70/30; Bruker BioSpin, Ettlingen, Germany) equipped with actively shielded 
gradients (B-GA12 gradient coil inserted into a B-GA20S gradient system) and a quadrature receive 
surface coil, actively decoupled from a volume resonator with 72 mm inner diameter.  
Anesthesia was performed using isoflurane and O2 mixture (2.5%–3.0% for induction, and  
0.7%–2.5% for maintenance). Respiratory frequency was maintained between 40 and 60 breaths/min. 
Body temperature was maintained between 36.5 and 37.5 °C with a recirculating water system 
incorporated in the animal bed, and measured with a rectal probe. Breathing rate and temperature were 
constantly monitored (SA Instruments, Inc., New York, NY, USA). All animals were explored in 
coronal and axial planes with T2-weighted high resolution MR images. For this, a RARE sequence 
was chosen; field of view (FOV), 19.2 × 19.2 mm; matrix (MTX), 256 × 256 (0.075 × 0.075 mm/pixel); 
number of slices (NS), 10; slice thickness (ST), 0.50 mm; echo time (TE), 12 ms (effective TE, 36 ms); 
recycling time (TR) 4.2 s; number of averages (NA), 4; total acquisition time (TAT), 6 min 43 s. 
4.5. Bioluminiscence Analysis 
Inhalatory anesthesia with O2 and isofluorane mixture was delivered to athymic mice before image 
acquisition: induction was performed outside the bioluminiscence chamber (isofluorane 4% at 2 L/min) 
and maintenance inside the chamber (isofluorane 2% at 2 L/min) during acquisition. Animals were 
placed in prone position. The photons recorded in the images were quantified and analyzed using 
Living Image 4.1 image analysis software (Caliper, LifeSciences Hopkinton, MA, USA). The number 
of photons was expressed as photon counts per second (p/s). The parameter chosen for treatment 
evaluation was the Average Radiance (p/s/cm2/sr). Luciferin solution (D-Luciferin Firefly potassium 
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salt, L-8220–Biosynth AG) was prepared according to the data sheet. Intraperitoneal injection of 
luciferin solution (200 µL/20 g) was applied 10 min before imaging. The planned period of time for 
image acquisition was the same for all animal groups (control, radiotherapy and radiotherapy plus 
temozolomide) before and after treatment.  
Background signals were subtracted from all the bioluminescence cranial measurements as part of 
image analysis. To this end, a healthy mouse (not inoculated with tumoral cells) received luciferin 
solution (200 µL/20 g) intraperitoneally 10 min before imaging. 
4.6. Histological Analysis 
During the organ-specific selection procedure, after the mice had been sacrificed we examined the 
presence of green fluorescent cells in lungs, liver, suprarenal glands, ovaries, lymph nodes and brain 
under fluorescent microscopy. Finally, soft tissues were fixed with formalin and embedded in paraffin. 
Brains were optionally fixed in 4% paraformaldehyde 24 h, followed by 30% sucrose 24 h and  
OCT-embedded (tissue freezing medium, Sakura Tissue-Tek®) before being frozen in dry ice. 
Samples, which were kept at −80 °C, were cut into 5 μm coronal sections for evaluation. The cryostat 
was at −27 °C.  
Metastatic involvement was explored in each section by classic hematoxylin-eosin (H&E).  
4.7. Therapeutic Protocols 
We used a combination of radiotherapy and chemotherapy to standardize a preclinical model which 
mimicked the clinical situation of brain metastasis development, in order to assess the efficacy of  
both treatments.  
4.8. Radiotherapy 
Under sterile conditions in a flux chamber, we anesthetized mice by intraperitoneal injection of 
ketamine (100 mg/Kg) and xylazine (10 mg/Kg). For irradiation mice were transported in a 
hermetically closed plastic box from the flux chamber to the scanner, where CT slices were performed 
in the head placed in a helical CT scanner device (Oncology Radiotherapy Service of the Catalan 
Oncology Institute, ICO, Hospital Duran i Reynals, L’Hospitalet de Llobregat, Spain), and then to the 
radiation treatment unit. A flexible and solid silicone gel, Bolus (Lorca Marín, S.A., 30007-Murcia. 
Spain), which has the same density as the body tissues, was used to obtain a reliable dose distribution 
of ionizing radiation at the prescribed depth. 
We used the Cadplan Treatment Planning Software (Varian dosimetry software, Darmstadt, 
Germany), to calculate the dose distribution (isodose curves) of ionizing radiation from the CT slices 
(Servei de Física Mèdica, ICO, L’Hospitalet de Llobregat, Spain). All treatment sessions were 
performed with a Linear Accelerator CLINAC-2100 device (Varian Oncology Systems, Darmstadt, 
Germany) for radiotherapy at the Oncology Radiotherapy Service, which allowed us to deliver 6 MV 
X-ray energy (SOR, ICO, L’Hospitalet de Llobregat, Spain).  
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4.9. Chemotherapy 
Mice were treated with temozolomide (TMZ), a novel oral alkylating agent with proven clinical 
activity in primary and recurrent gliomas and metastatic melanoma [32,55,56]. 100 mg TMZ (≥98% 
HPLC, solid T2577, Sigma-Aldrich Química, St. Louis, MO, USA) were resuspended in 0.5 mL of 
dimethyl sulfoxide (DMSO, D5879 Sigma-Aldrich, St. Louis, MO, USA) as vehicle with a final 
concentration of 200 mg/mL. To achieve homogeneity the solution was sonicated (UP50H Ultrasonic 
Processor, Hielscher, Ultrasound Technology, Teltow, Germany), delivering four 5 s pulses (each one 
with a 30% amplitude) every five seconds. Aliquots were frozen at −80 °C.  
Mice were orally administered 60 mg/Kg/day in a 200 µL final volume (20 µL of TMZ + DMSO 
solution and 180 µL of saline) using a flexible and sterile intragastric catheter (Instech Solomon, 
Plymouth, PA, USA). The control group comprised mice orally administered 20 µL DMSO and 180 
µL saline solution every day for five days (days 1–5). 
4.10. Statistics 
For survival times for V3 (LV) and V5 (CA) groups, we used the non-parametric Mann-Whitney test. 
The bioluminescence data were transformed using the log(1 + x) function (where x = AvR), in order 
to obtain a more regular and positive distribution. Subsequently, these data were normalized by 
subtracting the first observation (day 14) from each of the following ones. The Student t test was used 
to compare the treatment groups. Survival curves for each treatment were estimated via the  
Kaplan-Meier method, and the Log-Rank test was used to assess if they were significantly different. 
p-values lower than 0.05 were considered significant. 
5. Conclusions  
In conclusion we have generated a new breast cancer brain metastatic cellular model, which 
induced parenchymal brain metastasis within a 60-day time window post-injection in carotide in all 
cases. This versatile model mimics clinical brain metastasis growth and can be analyzed in vivo when 
mice are submitted to therapeutic protocols. Moreover, we have optimized a new preclinical 
chemoradiotherapy protocol proved useful for the study of radiation response/resistance in brain 
metastasis, either alone or in combination with new sensitizing agents.  
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